To investigate the effect of magnesium sulfate combined with pancreatic kallikrein for treating pregnant women with severe preeclampsia (SPE), and to study its influence on the levels of serum neutrophil gelatinase-associated lipocalin (NGAL), soluble vascular endothelial growth factor receptor 1 (sFlt -1), and soluble endothelial factor (sEng) of these women. Methods: 85 women with SPE were selected and were divided into control group (n=42) and observation group (n=43) by the random number method between December 2016 and December 2019. The women in the control group were treated with magnesium sulfate, and the women in the observation group were treated with magnesium sulfate combined with pancreatic kallikrein. The clinical effect, blood pressure, uterine artery and umbilical artery blood flow, serum NGAL, sFlt-1 and sEng levels, the levels of inflammatory factors ［interleukin-10 (IL-10), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)］, and delivery outcomes of the women were compared between the two groups. Results: The effective rate of the women in the observation group (88.4%) was significant higher than that (64.3%) of the women in the control group (P<0.05). After treatment, the values of SBP, DBP and MAP, the values of PI and S/D of umbilical artery and uterine artery, serum Ngal, sflt-1, sEng, IL-6, and TNF-αlevels of the women in the observation group were significant lower than those of the women in the control group, but the IL-10 level of the women in the observation group was significant higher (all P<0.05). The delivery outcomes of the women in the observation group were significant better than those of the women in the control group (P<0.05). Conclusion: Magnesium sulfate combined with pancreatic kallikrein for treating pregnant women with SPE is markedly effective, which can stabilize blood pressure, reduce vascular resistance, decrease serum NGAL, sFlt-1, sEng, IL-4 and IL-6 levels, and improve delivery outcomes.